AbbVie Sets Out Expectations For 2024 Humira Competition
Offers Overview Of Anticipated Impact From Adalimumab Biosimilars In The Year Ahead
As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.
You may also be interested in...
With adalimumab biosimilars slow to capture market share from Humira in the US, AbbVie says that erosion for the top-selling brand is continuing to go “exceptionally well” for the originator.
AbbVie has set out its expectations for US biosimilar competition to Humira this year, predicting 37% brand erosion with pressures ramping up in the second half of 2023 as Amgen’s Amjevita is followed into the market by numerous other adalimumab rivals. Management also commented on pricing dynamics after Amgen offered a dual-discount strategy.
Hot on the heels of rival Celltrion, Jamp and partner Alvotech have now launched their own higher-strength adalimumab biosimilar in Canada, setting up a showdown between their Simlandi version and Celltrion’s Yuflyma.